FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population

FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population

The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate such intensive treatments.

Source: https://ift.tt/2XkRZKo